Follow-On Biologics: Is Your Product Patent Portfolio Ready?


As the research and scientific discoveries of the past decade have moved beyond the lab into the commercial application of biotechnology, explosive growth has occurred in related sectors that require intellectual property protection for survival. Finnegan has advised biotech pioneers on every aspect of intellectual property, including patenting groundbreaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others. In fact, Finnegan successfully represented Eli Lilly and Company in a lawsuit involving the first marketed product produced by biotechnology—human insulin.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Finnegan | Attorney Advertising

Written by:


Finnegan on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.